Collegium Pharmaceutical, Inc (COLL) insider trading

Every open-market stock purchase and sale by Collegium Pharmaceutical, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Insiders sold $7.2M over the last 12 months (11 sales). No open-market buys.
  • Last insider buy: Paul Brannelly (CFO), $91.8K, 9 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $7.2M (11 sales). Last close $34.80 on Jun 10, 2026.

Recent COLL insider trades

DateInsiderTradeValue
Jun 8, 2026Gino Santini (Insider)Bought (not open market)—
May 18, 2026John Gordon Freund (Insider)Sold$681
May 15, 2026John Gordon Freund (Insider)Sold$143K
May 15, 2026John Gordon Freund (Insider)Bought (not open market)—
May 14, 2026Nancy Lurker (Insider)Bought (not open market)—
May 14, 2026Donovan Michael Glancy (Insider)Bought (not open market)—
May 14, 2026Gino Santini (Insider)Bought (not open market)—
May 14, 2026Garen G Bohlin (Insider)Bought (not open market)—
May 14, 2026Rita J. Balice-Gordon (Insider)Bought (not open market)—
May 14, 2026John Gordon Freund (Insider)Bought (not open market)—
May 14, 2026Carlos V Paya (Insider)Bought (not open market)—
May 13, 2026Nancy Lurker (Insider)Sold$162K
May 11, 2026Garen G Bohlin (Insider)Sold$323K
May 11, 2026Garen G Bohlin (Insider)Bought (not open market)—
Mar 18, 2026David Dieter (VP)Sold$488K
Mar 17, 2026David Dieter (VP)Sold (not open market)$316K
Mar 9, 2026David Dieter (VP)Sold$228K
Mar 3, 2026Scott Dreyer (C-suite exec)Sold$1.9M
Mar 3, 2026Scott Dreyer (C-suite exec)Sold$146K
Feb 10, 2026Colleen Tupper (CFO)Sold (not open market)$1.2M
Feb 10, 2026Scott Dreyer (C-suite exec)Sold (not open market)$1M
Feb 10, 2026Colleen Tupper (CFO)Sold (not open market)$555K
Feb 10, 2026Thomas B Smith (C-suite exec)Sold (not open market)$539K
Feb 10, 2026Vikram Karnani (CEO)Sold (not open market)$528K
Feb 10, 2026Scott Dreyer (C-suite exec)Sold (not open market)$466K

Who's trading COLL

Get free alerts when an insider at Collegium Pharmaceutical, Inc files a new trade →